Sunbelt Securities Inc. Has $648,000 Position in Bristol Myers Squibb Company (NYSE:BMY)

Sunbelt Securities Inc. reduced its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 47.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,619 shares of the biopharmaceutical company's stock after selling 9,467 shares during the period. Sunbelt Securities Inc.'s holdings in Bristol Myers Squibb were worth $648,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. LaFleur & Godfrey LLC raised its position in Bristol Myers Squibb by 3.5% during the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after purchasing an additional 1,487 shares during the last quarter. Brighton Jones LLC raised its position in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG bought a new position in Bristol Myers Squibb during the 4th quarter worth $13,094,000. Whipplewood Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $82,000. Finally, NewEdge Wealth LLC lifted its position in shares of Bristol Myers Squibb by 23.7% in the 4th quarter. NewEdge Wealth LLC now owns 26,443 shares of the biopharmaceutical company's stock worth $1,496,000 after purchasing an additional 5,073 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In other news, EVP Samit Hirawat bought 4,250 shares of Bristol Myers Squibb stock in a transaction dated Friday, April 25th. The stock was purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.09% of the company's stock.

Bristol Myers Squibb Stock Performance

BMY opened at $46.34 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The company's fifty day moving average price is $47.90 and its two-hundred day moving average price is $53.92. Bristol Myers Squibb Company has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a market cap of $94.31 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 1.37 and a beta of 0.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the company posted ($4.40) earnings per share. The business's revenue was down 5.6% on a year-over-year basis. On average, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.35%. Bristol Myers Squibb's payout ratio is 92.88%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BMY. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price target on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Finally, William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $58.00.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.